Indofarma Addresses Potential Delisting Concerns

Background on Delisting Warning

The Indonesia Stock Exchange (BEI) has issued a list of 70 companies at potential risk of delisting as of December 30, 2025. PT Indofarma Tbk (INAF), a state-owned pharmaceutical company, is among the firms on this list. The delisting warning comes due to Indofarma's shares being suspended for nearly two years, starting from July 2, 2024.

Company's Response to Delisting Warning

Indofarma's management has responded to the delisting warning by detailing their ongoing restructuring efforts. According to Sahat Sihombing, the company's President Director, Indofarma is focusing on restructuring its financial and operational conditions. The restructuring process has led to the suspension of Indofarma's shares by the capital market authorities.

Restructuring and Future Plans

Sahat Sihombing emphasized that the company is fully committed to improving its financial and operational performance gradually and sustainably. The management aims to ensure the continuity of Indofarma's business operations while navigating through the challenging period. The company's efforts are centered on achieving a stable financial position and restoring its market presence.